Please assess the completion status of the following clinical trial:

Trial Title: Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed, informed consent.~2. Men and women greater than or equal to 55 years of age.~3. Recent development of RPED secondary to AMD.~4. ETDRS best corrected visual acuities of 20/40 to 20/320 (letter score of 73 to 25) in the study eye.~5. Willing and committed and able to return for all clinic visits and complete all study related procedures.~Exclusion Criteria:~1. Any prior treatment for neovascular AMD except dietary supplements or vitamins. (for patients in the treatment naïve group only)~2. Any prior or concomitant therapy with another investigational agent to treat neovascular AMD in the study eye.~3. Total lesion size greater than 12 disc areas.~4. Subretinal hemorrhage that is either 50% or more of the total lesion area or if the blood is under the fovea and is 1 or more disc areas in size in the study eye.~5. Scar or fibrosis making up greater than 50% of the total lesion in the study eye.~6. Scar, fibrosis or atrophy involving the center of the fovea.~7. Presence of a retinal pigment epithelial tear.~8. History of a vitreous hemorrhage within 4 weeks prior to initiation of the study.~9. Presence of other causes of choroidal neovascular membrane other than AMD.~10. History of clinical evidence of diabetic retinopathy, especially diabetic maculopathy or macular edema from other causes, including retinal vein occlusion or diabetes~11. Prior vitrectomy surgery in the study eye.~12. History of retinal detachment treatment in the study eye.~13. History of macular hole in the study eye.~14. Any intraocular/periocular surgery within 3 months of the initiation of the study.~15. Prior trabeculectomy or filtering surgery in the study eye.~16. Uncontrolled glaucoma, defined as a pressure greater than 25 mmHg despite treatment.~17. Active intraocular inflammation.~18. Active ocular/periocular infection.~19. Any history of uveitis.~20. Active scleritis or episcleritis.~21. Aphakia or pseudophakia with absence of posterior capsule (unless it occurred as a result of YAG posterior capsulotomy) in the study eye.~22. Previous radiation therapy in the region of the study eye.~23. History of corneal transplant or corneal dystrophy in the study eye.~24. Significant medial opacities including cataract that may interfere with visual acuity or fundus photography.~25. Any disease or ocular condition which, in the opinion of the investigator could either increase in the risk to the subject beyond what is expected from a standard procedure of intraocular injections or which may be considered contraindicated for the use of the investigational drug (VEGF Trap).~26. The use of long acting steroids systemically or intraocularly.~27. Any history of allergy to Proviodine or fluorescein sodium.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Eylea (Type: OTHER): The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete